Disease-A-Month
Volume 55, Issue 10 , Pages 592-641 , October 2009

Herbal Toxicity

References 

  1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. J Am Med Assoc. 1998;280:1569–1575
  2. Bent S, Ko R. Commonly used herbal medicines in the United States: A review. Am J Med. 2004;116:478–485
  3. Pal SK, Yogeshwer S. Herbal medicine: Current status and the future. Asian Pac J Cancer Prev. 2003;4:281–288
  4. http://www.fda.gov.Accessed August 1, 2008.
  5. Dietary supplement health and education Act of 1994, pub. L. Numbers 103-417. Stat 4325. 1994;
  6. Bown D. The Herb Society of America New Encyclopedia of Herbs and Their Uses. New York: Dorling Kindersley; 2001;p 18
  7. Williamson E. Drug interactions between herbal and prescription medicines. Drug Saf. 2003;26:1075–1092
  8. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere. 2003;52:1361–1371
  9. http://www.FDA.gov.Accessed September 1, 2008.
  10. Woolf AD, Watson WA, Smolinske S, et al. The severity of toxic reactions to Ephedra: Comparisons to other botanical products and national trends from 1993-2002. Clin Toxicol. 2003;43:347–355
  11. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Pub. L. No. 107-188, 116 Stat. 594 (January 23, 2002).
  12. Winslow L, Kroll D. Herbs as medicines. Arch Intern Med. 1998;158:2192–2199
  13. Miller L. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200–2211
  14. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246–252
  15. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. J Am Med Assoc. 2008;300:2867–2878
  16. Garrard J, Harms S, Eberly LE, et al. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med. 2003;163:2290–2295
  17. Watkins R. Herbal therapeutics: The top 12 remedies. Emerg Med. 2002;9:9–12
  18. Milton D. Using alternative and complementary therapies in the emergency setting. J Emerg Nurs. 1998;24:500–508
  19. Moss T. Herbal medicine in the emergency department: A primer for toxicities and treatment. J Emerg Nurs. 1998;24:509–513
  20. Palmer M. Dietary supplements: “Natural” is not always safe. Emerg Med. 1998;9:52–74
  21. Boyer E. Issues in the management of dietary supplement use among hospitalized patients. J Med Toxicol. 2005;1:30–34
  22. Saad B, Azaizeh H, Abu-Hijleh G, et al. Safety of traditional Arab herbal medicine. ECAM. 2006;3:433–439
  23. Dasgupta A, Bernard DW. Herbal remedies (Effects on clinical laboratory tests). Arch Pathol Lab Med. 2006;130:521–528
  24. Dasgupta A, Biddle DA, Wells A, et al. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: Elimination of interference by using a monoclonal chemilunimescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol. 2000;114:174–179
  25. Chow L, Johnson M, Wells A. Effect of the traditional Chinese medicines Chan Su, Lu-Shen-Wan, Dan Shen, and Asian ginseng on serum digoxin measurement by Tina-quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal. 2003;17:22–27
  26. Dasgupta A, Wu S, Actor J, et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays (Significant variation in digoxin-like immunoreactivity among commercial ginsengs). Am J Clin Pathol. 2003;119:298–303
  27. Dasgupta A, Tso G, Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. J Clin Lab Anal. 2008;22:295–301
  28. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: Resemblance to digoxin toxicity and therapeutic implications. Heart. 2003;89:e14
  29. Chi HT, Hong DZ, Hu WH, et al. Prognostic implications of hyperkalemia in toad toxin intoxication. Hum Exp Toxicol. 1998;17:343–346
  30. Chen KK, Kovarikova A. Pharmacology and toxicology of toad venom. J Pharm Sci. 1967;56:1535–1541
  31. Lyttle T, Goldstein D, Gartz J. Bufo toads and bufotenine: Fact and fiction surrounding an alleged psychedelic. J Psychoact Drugs. 1996;28:267–290
  32. Ko RJ. Safety of ethnic and imported herbal and dietary supplements. Clin Toxicol. 2006;44:611–616
  33. Huang WF, Wen KC, Hsiao ML, et al. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997;37:344–350
  34. Petty HR, Fernando M, Kindzelskii AL, et al. Identification of colchicine in placental blood from patients using herbal medicines. Chem Res Toxicol. 2001;14:1254–1258
  35. Li W, Fitzloff JF, Farnsworth NR, et al. Evaluation of commercial Ginkgo biloba dietary supplements for the presence of colchicine by high-performance liquid chromatography. Phytomedicine. 2002;9:442–446
  36. Ko RJ. Adulterants in Asian patent medicines. N Engl J Med. 1998;339:847
  37. Ko R, Wilson RD, Loscutoff S. PC-SPES. Urology. 2003;61:1292
  38. Holistic healing and natural alternative health care solutions. Miracle herbs: How to make and use herb preparations. http://www.healthynewage.com/makeherb.htmlAccessed December 26, 2008
  39. Dr Standley herbal preparations. http://www.drstandley.com/supplements_herbal_preparations.shtmlAccessed December 26, 2008
  40. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: Regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 2000;23:351–362
  41. Ernst E, Pittler MH. Risks associated with herbal medicine products. Wien Med Wochenschr. 2002;152:183–189
  42. Russo S, Mastropasqua M, Mosetti MA, et al. Low dose of liquorice can induce hypertension encephalopathy. Am J Nephrol. 2000;20:145–148
  43. Padiyara RS, Khan SF. A review of commonly used herbal medicines. ICHP Keeposted. 2006;9:22–36
  44. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a Ma Huang containing drink. J Clin Psychopharmacol. 1997;17:437–439
  45. Ephedra. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  46. Food and Drug Administration. HHS: Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; final rule. Fed Regist. 2004;69:6787–6854
  47. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing Ephedra alkaloids. N Engl J Med. 2000;343:1833–1838
  48. Morgenstern LB, Viscoli CM, Kernan WN, et al. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;60:132–135
  49. Cohosh B. Natural medicines database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  50. Jones TK, Lawson BM. Profound neonatal congestive heart failure caused by maternal consumption of blue cohosh herbal medication. J Pediatr. 1998;132:550–552
  51. Wright IM. Neonatal effects of maternal consumption of blue cohosh. J Pediatr. 1999;132:550–552
  52. Ko RJ. A U.S. Perspective on the adverse reactions from traditional Chinese medicines. J Chin Med Assoc. 2004;67:109–116
  53. Aconite. Natural medicines database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  54. Lin CC, Chan TY, Deng JF. Clinical features and management of herb-induced aconitine poisoning. Ann Emerg Med. 2004;43:574–579
  55. But PP, Tai YT, Young K. Three fatal cases of herbal aconite poisoning. Vet Hum Toxicol. 1994;36:212–215
  56. Yeih DF, Chiang FT, Huang SKS. Successful treatment of aconitine induced life threatening ventricular tachyarrhythmia with amiodarone. Heart. 2000;84:E8
  57. Lin TJ, Lu CC, Chen KW, et al. Outbreak of obstructive ventilatory impairment associated with consumption of Sauropus androgynus vegetable. Clin Toxicol. 1996;34:1–8
  58. Spyker D, Love LA, Brooks SM. An outbreak of pulmonary poisoning. J Toxicol Clin Toxicol. 1996;34:15–20
  59. Aristolochia. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  60. Supplements D (Aristolochic acid: U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition). http://www.cfsan.fda.gov/∼dms/ds-bot.htmlAccessed: January 5, 2009
  61. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686–1692
  62. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–391
  63. Gingko. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  64. Bent S, Goldberg H, Padula A, et al. Spontaneous bleeding associated with ginkgo biloba: A case report and systematic review of the literature. J Gen Intern Med. 2005;20:657–661
  65. Kohler S, Funk P, Kieser M, et al. Influence of a 7 day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: A randomized, placebo controlled double-blind study in health volunteers. Blood Coagul Fibrinolysis. 2004;15:303–309
  66. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. J Am Med Assoc. 2008;300:2253–2262
  67. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline. Neurology. 2008;70:1809–1817
  68. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 1998;352:36
  69. Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis. 2003;167:367
  70. Bent S, Goldberg H, Padula A, et al. Spontaneous bleeding associated with Ginkgo biloba (A case report and systematic review of the literature). J Gen Intern Med. 2005;20:657–661
  71. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas with chronic gingko biloba ingestion. Neurology. 1996;46:1775–1776
  72. Siegers CP. Cytotoxicity of alkylphenols from Ginkgo biloba. Phytomedicine. 1999;6:281–283
  73. Morgenstern C, Biermann E. The efficacy of ginkgo special extract EGb 761 in patients with tinnitus. Int J Clin Pharmacol Ther. 2002;40:188–197
  74. Pennisi RS. Acute generalised exanthematous pustulosis induced by the herbal remedy Ginkgo biloba. Med J Aust. 2006;184:583–584
  75. Davydov L, Stirling AL. Stevens–Johnson syndrome with Ginkgo biloba. J Herb Pharmacother. 2001;1:65–69
  76. Haller C. Clinical approach to adverse effects and interactions related to herbal and dietary supplements. Clin Toxicol. 2006;44:605–610
  77. Dong quai. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  78. Monograph. Angelica sinensis (Dong quai). Altern Med Rev. 2004;9:429–433
  79. Nambiar S, Schwartz RH, Constantino A, et al. Hypertension in mother and baby linked to ingestion of Chinese herbal medicine. West J Med. 1999;171:152
  80. Lau CBS, Ho TCY, Chan TWL, et al. Use of dong quai (Angelica sinensis) to treat peri- and postmenopausal symptoms in women with breast cancer: Is it appropriate?. Menopause. 2005;12:734–740
  81. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause. 2002;9:145–150
  82. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999;19:870–876
  83. Corrigan JJ, Marcus FL. Coagulopathy associated with vitamin E ingestion. J Am Med Assoc. 1974;230:1300–1301
  84. Heck AM, DeWitt BA, Lukes AL, et al. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57:1221–1227
  85. Fiebich BL, Appel K. Anti-inflammatory effects of willow bark extract. Clin Pharmacol Ther. 2003;74:96
  86. Schmid B, Kotter I, Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur J Clin Pharmacol. 2001;57:387–391
  87. Bark W. Natural medicines database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  88. Biegert C, Wagner I, Ludtke R, et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double-blind controlled trials. J Rheumatol. 2004;31:2121–2130
  89. Chrubasik S, Eisenberg E, Balan E, et al. Treatment of low back pain exacerbations with willow bark extract: A randomized double-blind study. Am J Med. 2000;109:9–14
  90. Food and Drug Administration, HHS: Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's syndrome warning (Final rule). Fed Regist. 2003;68:18861–18869
  91. Grape. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  92. Freedman JE, Parker C, Li L, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001;103:2792–2798
  93. Nuttall SL, Kendall MJ, Bombardelli E, et al. An evaluation of the antioxidant activity of a standardized grape seed extract, Leucoselect. J Clin Pharm Ther. 1998;23:385–389
  94. Bernstein DI, Bernstein CK, Deng C, et al. Evaluation of the clinical efficacy and safety of grapeseed extract in the treatment of fall seasonal allergic rhinitis: A pilot study. Ann Allerg Asthma Immunol. 2002;88:272–278
  95. Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with kava, a herbal remedy. Br J Med. 2001;322:139
  96. Escher M, Desmeules J, Giostra E, et al. Drug points: Hepatitis associated with kava, a herbal remedy for anxiety. BMJ. 2001;322:139
  97. Russmann S, Lauterberg BH, Hebling A. Kava hepatotoxicity. Ann Intern Med. 2001;135:68
  98. Liver toxicity with kava. Pharmacist's Lett/Prescriber's Lett. 2001;18:180115
  99. Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava-containing products—United States, Germany, and Switzerland, 1999-2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065–1067
  100. Kava. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  101. Neff GW, Reddy R, Durazo FA, et al. Letters to the editor: Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma Huang or usnic acid. J Hepatol. 2004;41:1061–1067
  102. Borum ML. Abstract: Fulminant exacerbation of autoimmune hepatitis following the use of Ma Huang. Am J Gastroenterol. 2000;95:2566
  103. Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion (the broadening spectrum of liver injury caused by herbal medications). J Am Med Assoc. 1995;273:489–490
  104. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med. 1997;157:913–919
  105. Food and Drug Administration, FDA. Advice to chaparral users. http://www.fda.gov/bbs/topics/ANSWERS/ANS00456.htmlAccessed: January 14, 2009
  106. Furbee RB, Barlotta KS, Allen MK, et al. Hepatotoxicity associated with herbal products. Clin Lab Med. 2006;26:227–241
  107. Chaparral. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  108. Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992;117:129–132
  109. Mostefa-Kara N, Pauwels A, Pines E, et al. Fatal hepatitis after herbal tea. Lancet. 1992;340:674
  110. Zhou S, Koh HL, Gao Y, et al. Herbal bioactivation: The good, the bad and the ugly. Life Sci. 2004;78:935–938
  111. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause. 2008;15:628–638
  112. American mistletoe. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  113. European mistletoe. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  114. Huber R, Barth H, Schmitt-Graff A, et al. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med. 2000;6:305–310
  115. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer. 2001;37:23–31
  116. Heinzerling L, von Baehr V, Liebenthal C, et al. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol. 2006;26:347–359
  117. Timoshenko AV, Cherenkevich SN, Gabius HJ. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother. 1995;49:153–158
  118. Grossarth-Matichek R, Kiene H, Baumgartner SM, et al. Use of iscador, an extract of European mistletoe (Viscum album), in cancer treatment: Prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57–58
  119. Schoffski P, Breidenbach I, Krauter J, et al. Weekly 24 h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours. Eur J Cancer. 2005;41:1431–1438
  120. Pennyroyal. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  121. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996;124:726–734
  122. Mack RB. Boldly they rode…into the mouth of hell (pennyroyal oil toxicity). NC Med J. 1997;58:456–457
  123. Sullivan JB, Rumack BH, Thomas H, et al. Pennyroyal oil poisoning and hepatotoxicity. J Am Med Assoc. 1979;242:2873–2874
  124. Bakerink JA, Gospe SM, Dimand RJ, et al. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics. 1996;98:944–947
  125. Kingston R, Foley C. Herbal, traditional, and alternative medicines. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. Elsevier-Saunders, 2007:1077-88, 2007;(Ch. 68):1077-88.
  126. Segelman A, Segelman FP, Karliner J, et al. Sassafras and herb tea-potential health hazards. J Am Med Assoc. 1976;236:477
  127. Ridker P, Ohkuma S, McDermott WV, et al. Hepatic veno-occlusive disease associated with the consumption of pyrrolizidine containing dietary substances. Gastroenterology. 1985;88:1050
  128. Steenkamp V, Stewart MJ, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit. 2000;22:302–306
  129. Chojkier M. Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids. J Hepatol. 2003;39:437–446
  130. Wadleigh M, Ho V, Momtaz P, et al. Hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451–462
  131. Bladderwrack. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 11, 2008
  132. Teas J, Pino S, Critchley A, et al. Variability of iodine content in common commercially available edible seaweeds. Thyroidology. 2004;14:836–841
  133. Baker DH. Iodine toxicity and its amelioration. Exp Biol Med. 2004;229:473–478
  134. Pye KG, Kelsey SM, House IM, et al. Severe dyserythropoeisis and autoimmune thrombocytopenia associated with ingestion of kelp supplement. Lancet. 1992;339:1540
  135. Skibola CF. The effect of fucus vesiculosus, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: A case report. BMC Complement Altern Med. 2004;4:10
  136. Shilo S, Hirsch HJ. Iodine induced hyperthyroidism in a patient with a normal thyroid gland. Postgrad Med J. 1986;62:661–662
  137. Shintani S, Murase H, Tsukagoshi H, et al. Glycyrrhizin (licorice) induced hypokalemic myopathy: Report of 2 cases and review of the literature. Eur Neurol. 1992;32:44–51
  138. Maliacal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol. 2001;53:1323–1329
  139. Aloe. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 11, 2008
  140. Wilkinson JM. Effect of ginger tea on the fetal development of Sprague-Daley rats. Reprod Toxicol. 2000;14:507–512
  141. Marcus D, Snodgrass WR. Do no harm: Avoidance of herbal medicines during pregnancy. Obstet Gynecol. 2005;105:1119–1122
  142. Banerjee S, Sharma R, Kale RK, et al. Influence of certain essential oils on carcinogen metabolizing enzymes and acid soluble sulfhydryls in mouse liver. Nutr Cancer. 1994;21:263–269
  143. Miyoshi N, Nakamura Y, Ueda Y, et al. Dietary ginger constituents, galanals A and B, are potent apoptosis in human T lymphoma Jurkat cells. Cancer Lett. 2003;199:113–119
  144. Backgon J. Ginger in preventing nausea and vomiting of pregnancy: A caveat due to its thromboxane synthetase activity and effect on testosterone binding. Eur J Obstet Gynecol Reprod Bio. 1991;42:163–164
  145. Kuichi F, Iwakami S, Shibuya M, et al. Inhibition of prostaglandin and leukotriene synthesis by ginerols and diarylheptanoids. Chem Pharm Bull. 1992;40:387–391
  146. Garlic. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 11, 2008
  147. St John's Wort. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  148. Chuang CH, Doyle P, Wang JD, et al. Herbal medicines used during the first trimester and major congenital malformations: An analysis of data from a pregnancy cohort study. Drug Saf. 2006;29:537–548
  149. Heinrich M. Ethnobotany and natural products: The search for new molecules, new treatments of old diseases or a better understanding of indigenous cultures. Curr Top Med Chem. 2003;3:141–154
  150. Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines—A systematic review. Acta Psychiatr Scand. 2003;108:83–91
  151. Ginseng P. Natural medicines database (Therapeutic Research Faculty. Stockton, CA). http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 2, 2008
  152. Tamaoki J, Nakata J, Kawatani K, et al. Ginsenoside-induced relaxation of human bronchial smooth muscle via release of nitric oxide. Br J Pharmacol. 2000;130:1859–1864
  153. Keum YS, Park KK, Lee JM, et al. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett. 2000;150:41–48
  154. Moon J, Yu SJ, Kim HS, Sohn J. Induction of G(1) cell cycle arrest and p27(K 1) increase by panaxydol isolated from Panax ginseng. Biochem Pharmacol. 2000;59:1109–1116
  155. Kim SH, Park KS. Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol Rev. 2003;48:511–513
  156. Sievenpiper JL, Arnason JT, Leiter LA, et al. Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: The role of ginsenosides. J Am Coll Nutr. 2004;23:248–258
  157. Vuksan V, Stavro MP, Sievenpiper JL, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 2000;23:1221–1226
  158. Pan SJ, Ding Z, Ivy JL. Ginseng's effects on glucose tolerance and mRNA profiles in a animal model of type II diabetes. Altern Ther Health Med. 2001;7:S26
  159. Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: Report of a possible case. J Clin Psychopharmacol. 1995;15:447–448
  160. Valerian. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  161. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999;56:125–138
  162. Plushner SL. Valerian: Valerian officinalis. Am J Health Syst Pharm. 2000;57(328):333–335
  163. Eadie MJ. Could valerian have been the first anticonvulsant?. Epilepsia. 2004;45:1338–1343
  164. Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. 2004;98:353–358
  165. Fernandez S, Wasowski C, Paladini AC, et al. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol Biochem Behav. 2004;77:399–404
  166. Willey LB, Mady SP, Cobaugh DJ, et al. Valerian overdose: A case report. Vet Hum Toxicol. 1995;37:364–365
  167. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. [Letter to the editor] J Am Med Assoc. 1998;280:1566–1567
  168. Jimson weed. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  169. Hassell LH, MacMillan MW. Acute anticholinergic syndrome following ingestion of angel's trumpet tea. Hawaii Med J. 1995;54:669–670
  170. Passionflower. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  171. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol. 2001;78:165–170
  172. Aoyagi N, Kimura R, Murata T. Studies on Passiflora incarnata dry extract (I. Isolation of maltol and pharmacological action of maltol and ethyl maltol). Chem Pharm Bull. 1974;22:1008–1013
  173. Salgueiro JB, Ardenghi P, Dias M, et al. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav. 1997;58:887–891
  174. Akhondzadeh S, Naghavi HR, Shayeganpour A, et al. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363–367
  175. Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol. 2000;38:63–66
  176. Eucalyptus. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  177. Gray AM, Flatt PR. Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. J Nutr. 1998;128:2319–2323
  178. Silva J, Abebe W, Sousa SM, et al. Analgesic and anti-inflammatory effects of essential oils of eucalyptus. J Ethnopharmacol. 2003;89:277–283
  179. Juergens UR, Dethlefsen U, Steinkamp G, et al. Anti-inflammatory activity of 1,8-cineol (eucalyptol) in bronchial asthma: A double-blind placebo-controlled trial. Respir Med. 2003;97:250–256
  180. Burkhard PR, Burkhardt K, Haenggeli CA, et al. Plant-induced seizures: Reappearance of an old problem. J Neurol. 1999;246:667–670
  181. Darben T, Cominos B, Lee CT. Topical eucalyptus oil poisoning. Australas J Dermatol. 1998;39:265–267
  182. Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression: An overview and meta-analysis of randomized clinical trials. BMJ. 1996;313:253–258
  183. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomized multicenter study of treatment for eight weeks. BMJ. 1999;319:1534–1539
  184. Gaster B, Holroyd J. St. John's wort for depression. Arch Intern Med. 2000;160:152–156
  185. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med. 2000;132:743–756
  186. Schrader E. Equivalence of St. John's wort extract (ze 117) and fluoxetine: A randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61–68
  187. Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (li 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther. 2000;22:411–419
  188. Szegedi A, Kohnen R, Dienel A, et al. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St. John's wort): Randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330:503
  189. Shelton RC. St. John's wort for the treatment of depression. Lancet Neurol. 2002;1:275
  190. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and Dysthymia. Ann Intern Med. 2000;132:738–742
  191. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: A randomized, placebo-controlled trial. J Am Med Assoc. 2001;285:1978–1986
  192. de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. John's wort. Am J Health Syst Pharm. 2002;59:545–547
  193. Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum. Pharmacopsychiatry. 2001;34:45–49
  194. Schule C, Baghai T, Ferrera A, et al. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry. 2001;34:S127–S133
  195. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci. 2001;68:1593–1605
  196. Jakovljevic V, Popovic M, Mimica-Dukic N, et al. Pharmacodynamic study of Hypericum perforatum L. Phytomedicine. 2000;7:449–453
  197. Schempp CM, Kirkin V, Simon-Haarhaus B, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene. 2002;21:1242–1250
  198. Southwell IA, Bourke CA. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's wort). Phytochemistry. 2001;56:437–441
  199. Bilia AR, Bergonzi MC, Morgenni F, et al. Evaluation of chemical stability of St. John's wort commercial extract and some preparations. Int J Pharm. 2001;213:199–208
  200. Hubner WD, Kirste T. Experience with St. John's wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res. 2001;15:367–370
  201. Brown TM. Acute St. John's wort toxicity. Am J Emerg Med. 2000;18:231–232
  202. Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's wort. Am J Med. 2002;112:507–508
  203. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: A survey of effectiveness, safety, and tolerability. Pharmacotherapy. 2000;20:568–574
  204. Dean AJ, Moses GM, Vernon JM. Suspected withdrawal syndrome after cessation of St. John's wort. Ann Pharmacother. 2003;37:150
  205. Nutmeg. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  206. Sangalli BC, Chiang W. Toxicology of nutmeg abuse. Clin Toxicol. 2000;38:671–678
  207. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62:29–36
  208. Weiss J, Sauer A, Frank A, et al. Extracts and kavalactones of piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos. 2005;33:1580–1583
  209. Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007;35:240–245
  210. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66:338–345
  211. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598–604
  212. Hennessy M, Kelleher D, Spiers JP, et al. St. John's wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol. 2002;53:75–82
  213. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47–54
  214. Red clover. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  215. Saw Palmetto. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  216. Comfrey. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  217. Feverfew. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  218. Evening primrose oil. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  219. Echinacea. Natural Medicines Database. Therapeutic Research Faculty. Stockton, CA. http://www.naturaldatabase.com/(S(qku2mt55awj5j4iammokfc45))/home.aspx?cs=&s=NDAccessed January 15, 2008
  220. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134–138
  221. Ernst E. Harmless herbs? (A review of the recent literature). Am J Med. 1998;104:170–178
  222. Castot A, Larrey D. Hepatitis observed during a treatment with a drug or tea containing wild germander (Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance). Gastroenterologie Clin Biol. 1992;16:916–922
  223. Haller C, Anderson IB, Kim SY, et al. An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events Adverse Drug React. Toxicol Rev. 2002;21:143–150

PII: S0011-5029(09)00066-2

doi: 10.1016/j.disamonth.2009.05.001

Disease-A-Month
Volume 55, Issue 10 , Pages 592-641 , October 2009

Article Tools